What are the initial treatment approaches for Crohn's disease vs ulcerative colitis?

Initial Treatment Approaches for Crohn's Disease vs Ulcerative Colitis

Ulcerative Colitis: First-Line Treatment Strategy

For ulcerative colitis, aminosalicylates (mesalamine) are the cornerstone of initial therapy, with treatment tailored to disease extent and severity. 1

Proctitis (Rectal Disease Only)

• Mesalamine 1g suppository once daily is the preferred initial treatment for mild to moderately active proctitis 1
• Suppositories deliver medication more effectively to the rectum than foam or enemas and are better tolerated 1
• Combining topical mesalamine with oral mesalamine ≥2.4 g/day increases effectiveness over either alone 1
• Topical mesalamine is more effective than topical steroids 1

Left-Sided Colitis

• Combination therapy with mesalamine enema ≥1 g/day plus oral mesalamine ≥2.4 g/day is more effective than either topical or oral therapy alone 1
• Once-daily dosing is as effective as divided doses, improving adherence 1
• This combination approach is also more effective than topical steroids 1

Extensive Colitis

• Initial treatment should be mesalamine enema 1 g/day combined with oral mesalamine ≥2.4 g/day 1
• Systemic corticosteroids (prednisolone 40 mg daily) are appropriate for moderate to severe activity or when mesalamine fails 1
• Severe extensive colitis requires hospital admission for intensive intravenous treatment 1

Escalation for Refractory Disease

• Budesonide MMX 9 mg/day can be used for left-sided disease inadequately controlled with oral 5-ASA, providing an alternative before escalating to conventional steroids 1
• Biologics such as adalimumab are indicated for moderately to severely active ulcerative colitis when conventional therapy fails 2

---

Crohn's Disease: First-Line Treatment Strategy

For Crohn's disease, treatment depends on disease location and severity, with mesalamine appropriate only for mild ileal/ileocolonic disease, while corticosteroids are required for moderate to severe presentations. 3, 4

Mild Ileal or Ileocolonic Disease

• High-dose mesalamine 4 g daily is appropriate first-line therapy for mild ileal or ileocolonic Crohn's disease 3
• This directly targets intestinal inflammation rather than merely controlling symptoms 3
• Mesalamine is less effective in Crohn's disease than in ulcerative colitis and should not be used for moderate to severe disease 5, 6

Moderate to Severe Disease

• Oral prednisolone 40 mg daily is recommended for moderate to severe disease or when mesalamine fails 3, 4
• Taper over 8 weeks to prevent early relapse; avoid rapid reduction as this increases relapse risk 3, 4
• Budesonide 9 mg daily can be used for isolated ileo-caecal disease with moderate activity, though it is marginally less effective than prednisolone 3

Severe Ileitis

• Intravenous steroids (hydrocortisone 400 mg/day or methylprednisolone 60 mg/day) are indicated for severe ileitis 3
• Concomitant intravenous metronidazole is advisable when distinguishing active inflammation from septic complications is difficult 3

Maintenance and Steroid-Sparing Therapy

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day serve as adjunctive therapy and steroid-sparing agents for chronic disease 3
• These immunosuppressants carry increased risk of malignancy, particularly hepatosplenic T-cell lymphoma in adolescent and young adult males with inflammatory bowel disease 7
• Consider TPMT and NUDT15 testing before initiating azathioprine, as deficiency increases risk of severe myelotoxicity 7

Biologics for Refractory Disease

• Adalimumab is indicated for moderately to severely active Crohn's disease in adults and pediatric patients ≥6 years 2
• Adult dosing: 160 mg on Day 1,80 mg on Day 15, then 40 mg every other week starting Day 29 2

---

Key Distinguishing Features

Critical Differences in Initial Approach

• Ulcerative colitis responds well to aminosalicylates across all disease severities (mild to moderate), making mesalamine the clear first-line choice 1, 8
• Crohn's disease has limited response to aminosalicylates, which are only appropriate for mild ileal/ileocolonic disease; corticosteroids are required earlier in the treatment algorithm 3, 4, 5

Common Pitfalls to Avoid

• Do not use mesalamine as monotherapy for moderate to severe Crohn's disease—it is less efficacious than corticosteroids and delays appropriate treatment 5, 6
• Avoid rapid corticosteroid tapers in both conditions, as this increases early relapse rates 3, 4
• Do not overlook topical therapy in ulcerative colitis—combination topical plus oral mesalamine is significantly more effective than oral alone 1
• Consider alternative explanations for persistent symptoms in Crohn's disease (bacterial overgrowth, bile salt malabsorption, fibrotic strictures) rather than assuming active inflammation 4